萊茵生物(002166.SZ):實控人、董事長兼總經理秦本軍涉嫌操縱證券市場 被證監會立案
格隆匯5月10日丨萊茵生物(002166.SZ)公佈,公司於2023年5月10日接到公司實際控制人、董事長兼總經理秦本軍通知,其於當日收到中國證監會的《立案吿知書》(編號:證監立案字0382023077號),正文內容如下:“因你涉嫌操縱證券市場,根據《中華人民共和國證券法》《中華人民共和國行政處罰法》等法律法規,我會決定對你進行立案,特此吿知。”
本次調查事項系對秦本軍個人的調查,不會對公司的日常運營造成重大影響。秦本軍將積極配合證監會的調查工作,同時嚴格按照監管要求履行信息披露義務。
目前公司經營管理、業務及財務狀況正常,公司將持續關注上述事項的進展情況,並嚴格按照有關法律、法規的規定和要求,及時履行信息披露義務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.